1. Membrane Transporter/Ion Channel
  2. SGLT
  3. Luseogliflozin hydrate

Luseogliflozin hydrate (Synonyms: TS 071 hydrate)

Cat. No.: HY-10449A
Handling Instructions

Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM).

For research use only. We do not sell to patients.

Luseogliflozin hydrate Chemical Structure

Luseogliflozin hydrate Chemical Structure

CAS No. : 1152425-66-5

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM)[1][2].

IC50 & Target

IC50: 2.26 nM (SGLT2)[1][2]

In Vitro

Luseogliflozin can increase beta cell proliferation through the activation of the FoxM1/PLK1/CENP-A pathway via humoral factors thats act in an insulin/IGF-1 receptor-independent manner. Luseogliflozin increases beta cell proliferation in OSI-906-treated mice[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: βIRKO, IRS1KO and IRS2KO beta cells
Concentration: 100 nM
Incubation Time: 24 and 48 hours
Result: Cell Viability Assay[2] Treating cells with serum from the OSI-906 (200 nM) or OSI-906+Luseogliflozin(100 nM) group led to significantly increased cell viability in the latter group in the control, IRS1KO, IRS2KO, as well as the insulin receptor (IR)-deficient βIRKO beta cells.
In Vivo

SGLT2 inhibition with Luseogliflozin (10 mg/kg/daily; oral gavage) significantly ameliorates hyperglycaemia, but not hyperinsulinaemia, in the OSI-906(45 mg/kg)-treated mice. Luseogliflozin ameliorates hyperglycaemia induced by OSI-906[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J male mice aged 8 weeks old[2]
Dosage: 10 mg/kg/daily
Administration: Oral gavage; for 7 days between 08:00 and 09:00 hours
Result: Treatment significantly ameliorated the OSI-906 (45 mg/kg)-induced hyperglycaemia.
Clinical Trial
Molecular Weight

452.56

Formula

C₂₃H₃₂O₇S

CAS No.
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Luseogliflozin hydrate
Cat. No.:
HY-10449A
Quantity:
MCE Japan Authorized Agent: